InflaRx Analyst Ratings
InflaRx Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2023 | 125% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/31/2023 | 125% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/11/2023 | 125% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/12/2023 | 125% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/12/2023 | 425% | Raymond James | $25 → $21 | Maintains | Strong Buy |
| 04/21/2023 | 125% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 04/06/2023 | 525% | Raymond James | $8 → $25 | Maintains | Strong Buy |
| 04/05/2023 | 100% | Guggenheim | → $8 | Upgrades | Neutral → Buy |
| 04/05/2023 | 150% | HC Wainwright & Co. | $6 → $10 | Reiterates | → Buy |
| 04/05/2023 | — | LifeSci Capital | Upgrades | Market Perform → Outperform | |
| 03/23/2023 | 50% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/06/2023 | 50% | HC Wainwright & Co. | $8 → $6 | Maintains | Buy |
| 11/10/2022 | 100% | Raymond James | $7 → $8 | Maintains | Strong Buy |
| 08/08/2022 | 100% | HC Wainwright & Co. | $7 → $8 | Maintains | Buy |
| 05/13/2022 | -50% | Credit Suisse | $2.5 → $2 | Maintains | Underperform |
| 05/13/2022 | 75% | Raymond James | $15 → $7 | Maintains | Strong Buy |
| 05/13/2022 | 75% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 05/12/2022 | 0% | SVB Leerink | $6 → $4 | Maintains | Outperform |
| 03/25/2022 | 50% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 11/08/2021 | 275% | Raymond James | $14 → $15 | Maintains | Strong Buy |
| 10/28/2021 | 250% | Raymond James | → $14 | Upgrades | Outperform → Strong Buy |
| 08/06/2021 | 150% | Raymond James | $11 → $10 | Maintains | Outperform |
| 08/06/2021 | -37.5% | Credit Suisse | $2.8 → $2.5 | Maintains | Underperform |
| 05/13/2021 | -30% | Credit Suisse | $3.5 → $2.8 | Maintains | Underperform |
| 05/13/2021 | 175% | Raymond James | $12 → $11 | Maintains | Outperform |
| 03/26/2021 | 150% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 03/11/2021 | 300% | Guggenheim | → $16 | Upgrades | Neutral → Buy |
| 01/12/2021 | 200% | HC Wainwright & Co. | $11 → $12 | Maintains | Buy |
| 11/06/2020 | 150% | SVB Leerink | $7 → $10 | Upgrades | Market Perform → Outperform |
| 10/08/2020 | 175% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 07/31/2020 | 375% | Raymond James | $20 → $19 | Maintains | Outperform |
| 06/17/2020 | 200% | BTIG | → $12 | Initiates Coverage On | → Buy |
| 05/21/2020 | 400% | Raymond James | $10 → $20 | Maintains | Outperform |
| 05/07/2020 | 75% | SVB Leerink | $4 → $7 | Maintains | Market Perform |
| 04/30/2020 | 150% | Raymond James | → $10 | Upgrades | Market Perform → Outperform |
| 06/06/2019 | 50% | Baird | $58 → $6 | Downgrades | Outperform → Neutral |
| 03/29/2019 | 1350% | Baird | $62 → $58 | Maintains | Outperform |
| 02/22/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 01/29/2019 | 1450% | Baird | → $62 | Initiates Coverage On | → Outperform |
| 12/10/2018 | 1075% | Credit Suisse | → $47 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/12/2023 | 百分之一百二十五 | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年08月31日 | 百分之一百二十五 | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年08月11日 | 百分之一百二十五 | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年05月12日 | 百分之一百二十五 | HC Wainwright公司 | →$9 | 重申 | 购买→购买 |
| 2023年05月12日 | 425% | 雷蒙德·詹姆斯 | $25→$21 | 维护 | 强势购买 |
| 04/21/2023 | 百分之一百二十五 | HC Wainwright公司 | $10→$9 | 维护 | 买 |
| 04/06/2023 | 525% | 雷蒙德·詹姆斯 | $8→$25 | 维护 | 强势购买 |
| 04/05/2023 | 100% | 古根海姆 | →$8 | 升级 | 中性→购买 |
| 04/05/2023 | 150% | HC Wainwright公司 | $6→$10 | 重申 | →购买 |
| 04/05/2023 | - | 生活科学资本 | 升级 | 市场表现优于→ | |
| 03/23/2023 | 50% | HC Wainwright公司 | →$6 | 重申 | →购买 |
| 01/06/2023 | 50% | HC Wainwright公司 | $8→$6 | 维护 | 买 |
| 2022年11月10日 | 100% | 雷蒙德·詹姆斯 | $7→$8 | 维护 | 强势购买 |
| 2022/08/08 | 100% | HC Wainwright公司 | $7→$8 | 维护 | 买 |
| 2022年05月13日 | -50% | 瑞士信贷 | $2.5→$2 | 维护 | 表现不佳 |
| 2022年05月13日 | 75% | 雷蒙德·詹姆斯 | $15→$7 | 维护 | 强势购买 |
| 2022年05月13日 | 75% | HC Wainwright公司 | $11→$7 | 维护 | 买 |
| 2022年05月12日 | 0% | SVB Leerink | $6→$4 | 维护 | 跑赢大盘 |
| 03/25/2022 | 50% | SVB Leerink | $8→$6 | 维护 | 跑赢大盘 |
| 11/08/2021 | 275% | 雷蒙德·詹姆斯 | $14→$15 | 维护 | 强势购买 |
| 10/28/2021 | 250% | 雷蒙德·詹姆斯 | →$14 | 升级 | 跑赢→强势买入 |
| 08/06/2021 | 150% | 雷蒙德·詹姆斯 | $11→$10 | 维护 | 跑赢大盘 |
| 08/06/2021 | -37.5% | 瑞士信贷 | $2.8→$2.5 | 维护 | 表现不佳 |
| 2021/05/13 | -30% | 瑞士信贷 | $3.5→$2.8 | 维护 | 表现不佳 |
| 2021/05/13 | 175% | 雷蒙德·詹姆斯 | $12→$11 | 维护 | 跑赢大盘 |
| 03/26/2021 | 150% | HC Wainwright公司 | $12→$10 | 维护 | 买 |
| 03/11/2021 | 百分之三百 | 古根海姆 | →$16 | 升级 | 中性→购买 |
| 2021/12/01 | 百分之二百 | HC Wainwright公司 | $11→$12 | 维护 | 买 |
| 11/06/2020 | 150% | SVB Leerink | $7→$10 | 升级 | 市场表现优于→ |
| 10/08/2020 | 175% | HC Wainwright公司 | →$11 | 开始承保 | →购买 |
| 07/31/2020 | 375% | 雷蒙德·詹姆斯 | $20→$19 | 维护 | 跑赢大盘 |
| 06/17/2020 | 百分之二百 | BTIG | →$12 | 开始承保 | →购买 |
| 2020/05/21 | 400% | 雷蒙德·詹姆斯 | $10→$20 | 维护 | 跑赢大盘 |
| 05/07/2020 | 75% | SVB Leerink | $4→$7 | 维护 | 市场表现 |
| 04/30/2020 | 150% | 雷蒙德·詹姆斯 | →$10 | 升级 | 市场表现优于→ |
| 2019年06月06日 | 50% | 贝尔德 | $58→$6 | 评级下调 | 跑赢→中性 |
| 2019/03/29 | 1350% | 贝尔德 | $62→$58 | 维护 | 跑赢大盘 |
| 2019年02月22日 | - | 古根海姆 | 开始承保 | →购买 | |
| 2019年01月29日 | 1450% | 贝尔德 | →$62 | 开始承保 | →跑赢大盘 |
| 2018年12月10日 | 1075% | 瑞士信贷 | →$47 | 开始承保 | →跑赢大盘 |
What is the target price for InflaRx (IFRX)?
InflRx(IFRX)目标价是多少？
The latest price target for InflaRx (NASDAQ: IFRX) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $9.00 expecting IFRX to rise to within 12 months (a possible 125.00% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年9月12日报道了InflRx(纳斯达克代码：IFRX)的最新目标价。这家分析公司将目标价定为9美元，预计IFRX将在12个月内升至(可能上涨125.00)。过去一年，有13家分析公司公布了评级。
What is the most recent analyst rating for InflaRx (IFRX)?
InflRx(IFRX)的最新分析师评级是多少？
The latest analyst rating for InflaRx (NASDAQ: IFRX) was provided by HC Wainwright & Co., and InflaRx reiterated their buy rating.
分析师对InflRx(纳斯达克代码：IFRX)的最新评级由HC Wainwright&Co.提供，InflRx重申其买入评级。
When is the next analyst rating going to be posted or updated for InflaRx (IFRX)?
InflRx(IFRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与InflRx的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。InflRx的上一次评级是在2023年9月12日提交的，因此你应该预计下一次评级将在2024年9月12日左右提供。
Is the Analyst Rating InflaRx (IFRX) correct?
分析师对InflRx(IFRX)的评级正确吗？
While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a reiterated with a price target of $0.00 to $9.00. The current price InflaRx (IFRX) is trading at is $4.00, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的InflRx(IFRX)评级被重申，目标价在0.00美元至9.00美元之间。InflRx(IFRX)目前的交易价格为4.00美元，在分析师的预测范围内。